Food and Drug Administration Amendments Act of 2007
Latest Action
Became Public Law No: 110-85.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Food and Drug Administration Amendments Act of 2007 (Public Law 110-85) is a law enacted by the 110th Congress to amend and enhance the regulatory authority and oversight capabilities of the Food and Drug Administration (FDA). Although the official summary and full text are not provided, the law is known to strengthen the FDA's ability to monitor drug safety, improve post-market surveillance, and expand the agency's regulatory powers over pharmaceuticals and medical devices. The law was signed into law on September 27, 2007.
This law enhances the FDA's regulatory authority and oversight functions to improve drug and device safety and post-market monitoring.
- The law expands the FDA's authority to require post-market studies and clinical trials for drugs and devices.
- It increases the FDA's ability to monitor and ensure the safety of pharmaceuticals after they reach the market.
- The law includes provisions to improve transparency and reporting related to drug safety issues.
['Food and Drug Administration (FDA)', 'Pharmaceutical companies subject to FDA regulation', 'Healthcare providers relying on FDA-approved drugs and devices', 'Patients and consumers who use FDA-regulated products']
['Implementation challenges related to expanded FDA regulatory authority and oversight responsibilities.', 'Potential increased costs for pharmaceutical companies to comply with new post-market study requirements.', 'Oversight and enforcement mechanisms may require additional resources and coordination.']
The bill was passed by the House and became Public Law No: 110-85 on September 27, 2007, during the 110th Congress. It reflects congressional efforts to strengthen drug safety regulation following concerns about post-market drug risks. The law builds on existing FDA authorities to improve public health protections.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Improved drug safety monitoring may lead to earlier detection of adverse effects, potentially reducing public health risks.', 'Increased regulatory requirements could incentivize pharmaceutical companies to invest more in pre-market testing to avoid costly post-market studies.', 'Enhanced FDA oversight might influence innovation timelines and product development strategies within the pharmaceutical and medical device industries.']
The absence of an official bill summary and full text limits detailed analysis. Transparency around the specific provisions and their implementation is important to assess the full impact. Oversight mechanisms and resource allocation for the FDA to fulfill expanded responsibilities should be monitored to ensure effective enforcement and public health outcomes.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.